Clinical trials: Hepatitis C Genotype 1
Hepatitis C
Dose Escalation Study of IL-7 and Bi-therapy in HCV Patients Resistant After 12 Weeks of Bi-therapy (ECLIPSE 1)
This study will evaluate the safety of a new experimental drug, IL-7, in people with HCV infection resistant after 12 weeks of bi-therapy.
- Trial name
- ECLIPSE 1 (NCT01025596)
- Testing
- Interleukin-7
- Where
- 7 sites in France, Italy and 1 more
- Volunteers
- 10 people
- Sponsor
- Cytheris SA
Hepatitis C
A Study of Mericitabine in Combination With Telaprevir and Peginterferon Alfa-2a / Ribavirin in Participants With Chronic Hepatitis C
This randomized, double-blind, multi-center, parallel-group study will evaluate the sustained virologic response and the safety of mericitabine (RO5024048) (MCB) in combination with telaprevir (TVR) and peginterferon Alfa-2a…
- Trial name
- NCT01482390
- Testing
- Ribavirin, Mericitabine, Peginterferon Alfa-2a
- Where
- 39 sites in United States, Canada and 5 more
- Volunteers
- 80 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C
Observational Study of Patients With Chronic Hepatitis C Virus (HCV) Infected With HCV Genotype 1 Low Virus Load (LVL 1) and Effect of PegIntron Plus Rebetol Treatment (Study P04793 Part 2)
The purpose of this observational study was to provide summary data from participants who relapsed at the end of the follow-up phase after 24 weeks of treatment with standard care PegIntron plus ribavirin in Part 1 of the study…
- Trial name
- NCT01054742
- Testing
- Standard of Care PegIntron, Standard of Care Ribavirin
- Volunteers
- 2 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
Early Access Program of Telaprevir With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects
The purpose of this early access program is to provide telaprevir to patients with a specific type of hepatitis C viral infection (termed 'genotype 1') who are expected to benefit from telaprevir-based therapy but who reside in…
- Trial name
- NCT01508286
- Testing
- Telaprevir + peginterferon alfa + ribavirin, peginterferon alfa + ribavirin
- Where
- 128 sites in Australia, Austria and 13 more
- Sponsor
- Janssen-Cilag International NV
Chronic Hepatitis C
Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy
This study will evaluate the efficacy and safety of MP-424 with Peginterferon Alfa-2b (PEG-IFN) and Ribavirin (RBV) in patients with (Genotype 1) hepatitis C, who relapsed after previous treatment.
- Trial name
- NCT00780910
- Testing
- MP-424, Ribavirin, Peginterferon Alfa-2b
- Where
- Japan
- Volunteers
- 109 people
- Sponsor
- Tanabe Pharma Corporation